MicroApproach Medical Secures Tens of Millions in Series B+ Funding to Accelerate Launch of Over 30 New Neurovascular Products Including Trexcel™14 Micro Guidewires

VCBeat has learned that Shenzhen Mapuchi Medical Technology Co., Ltd. (hereinafter referred to as "Mapuchi Medical") recently completed a financing round worth tens of millions of yuanSeries B+ Financing Round, Exclusively Led by Nanjing High-Tech New Deepened Equity Investment Partnership (L.P.). Mapuchi Medical stated that the funds from this round will be used to expand its R&D center in Japan, increase R&D personnel, and prioritize the rapid market launch of its neurointerventional product series.

(Shenzhen Mapuchi Medical Japan R&D Center)

Shenzhen Mapuchi Medical Technology Co., Ltd. was established in 2015, focusing on the research and development of interventional guidewires and catheters. Starting with interventional access products, Mapuchi Medical has developed a series of product lines, including hydrophilic-coated guidewires, micro-guidewires, microcatheters, and aspiration catheters, covering fields such as coronary, peripheral, and neuro-interventional procedures.

Previously, Mapuchi Medical received investments from institutions such as Fortune Capital, Sanze Venture Capital, and Ruifeng Kangqi. Fu Xuesen, Chairman of Mapuchi Medical, stated, “The injection of capital has broadened the company’s strategic thinking on product portfolio layout, accelerated the pace of product research and development, and promoted the company’s comprehensive growth.”

In Fu Xuesen’s view, the reason Shenzhen Mapuchi Medical Technology Co., Ltd. has been favored by renowned investment institutions is that Mapuchi MedicalExceptional R&D Team, Breakthrough Innovative Technologies, and Strategic Product Portfolio。

In terms of team composition, Mapuchi Medical has recruited a group of senior R&D engineers from the interventional industry in China and Japan, all of whom possess over ten years of experience in interventional product development.

From a technical perspective, Mapuchi Medical has established R&D centers in both China and Japan. Through years of collaborative efforts by its Chinese and Japanese teams, the company has overcome numerous key core processes, with several breakthrough technologies being first-of-their-kind in China. Furthermore, Mapuchi Medical has mastered critical product process challenges and manufacturing technologies, positioning it as one of the few innovative enterprises in China capable of fully independent R&D and production.

In terms of product portfolio, Mapuchi Medical has completed the R&D and mass production of neuro micro-guidewires (Trexcel™14), peripheral micro-guidewires (DrianPro™), PTCA guidewires (Rapidgo™), and steerable guidewires (Limcess™). Meanwhile, it has also completed the R&D and mass production of aspiration catheters (Wisucker™) and microcatheters (Rapidthrough™). Currently, Mapuchi Medical has achieved a comprehensive layout with a full series of access product portfolios covering neurovascular, peripheral, and coronary applications.

(Mapuchi Medical Product Portfolio)

In addition, leveraging its technological expertise in access-related products and deep collaboration with clinical experts, Mapuchi Medical continues to develop innovative solutions that closely align with clinical needs. Fu Xuesen revealed, “From 2021 to 2022, Mapuchi Medical will launch more than 30 new products for sale.”

In the future, Mapuchi Medical will continue to deepen its presence in the interventional field, drive corporate development through innovation, increase R&D investment, and expand its China-Japan R&D team. The company will prioritize the research, development, manufacturing, and commercialization of innovative neurointerventional products, while simultaneously advancing market entry and sales in overseas regions such as Europe, Japan, and the United States, thereby enhancing its international brand influence.

Zhu Jin, Investment Director at Nanjing High-Tech New Deepened Equity Investment Partnership (L.P.), stated, “With the growing prevalence of minimally invasive surgeries, interventional consumables, particularly access products, are experiencing rapid growth and boasting broad application prospects in China. Against the backdrop of centralized volume-based procurement, companies that truly possess core technologies and manufacturing processes will have significant development opportunities. Shenzhen Mapuchi Medical Technology Co., Ltd. has an international R&D team, solid industrialization and implementation capabilities, and the potential to become a comprehensive platform for interventional devices. We are optimistic about Mr. Fu’s team and believe that, under his leadership, an increasing number of high-quality domestically produced products will gain recognition in the Chinese healthcare market, ultimately realizing the vision of ‘Made in China, Serving the World.’”

Neovision Capital is a professional firm specializing in venture capital, innovation-driven investments, and mergers and acquisitions within the healthcare and high-tech sectors. Since its establishment in late 2015, it has invested in multiple high-growth enterprises in the biopharmaceutical and high-tech fields. Representative portfolio companies in the biopharmaceutical sector include Bioswift (688399), Allist Pharmaceuticals (688578), Yimai Yangguang, Rendu Biology, Jiangsu Jiankeng Pharmaceutical, Zhengya Dental, ACROBiosystems, Hualan Pharmaceutical Packaging, Newreat Medical, and Houkai Medical.